AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05681702
Drug: prasugrel or ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After at least 30 days of DAPT \[with aspirin 81-mg od and a potent P2Y12 inhibitor (prasugrel 10 mg od or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will drop aspirin and continue prasugrel or ticagrelor.
Trial: NCT05972681
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 milliliters (ml) of bupivacaine 0.50% injected to the vaginal laceration site.
Trial: NCT05671510
Drug: Gotistobart
RxNorm normalized name: Gotistobart
DrugBank: Gotistobart (DB19100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gotistobart will be administrated through IV infusion over 60 minutes, once every 21 days in assigned dose.
Trial: NCT05671510
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel will be administrated through IV infusion over 60 minutes, once every 21 days in 75mg/m2 dose.
Trial: NCT05570006
Drug: ABBV-668
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT06373146
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06373146
Drug: Mibavademab
RxNorm normalized name: Mibavademab
DrugBank: Mibavademab (DB16673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05132153
Drug: Milrinone
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: will be given by nebulization
Trial: NCT06373146
Drug: Tirzepatide-Placebo
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06373146
Drug: Mibavademab-Placebo
DrugBank: Mibavademab (DB16673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06780865
Drug: Antihypertensive treatment with Arotinolol or Amlodipine or Clonidine
RxNorm normalized name: Medicated Pad or Tape
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Almar 10 mg orally once daily between 8:00 PM and midnight. At the subsequent visit, if nocturnal blood pressure remains above the target of \<120/70 mmHg, Amlodipine Besylate will be added at a dose of 2.5 mg to 5 mg orally once daily. Should nocturnal blood pressure still not achieve the target at the following visit, Clonidine Hydrochloride 75 µg will be added to the regimen. The target for nocturnal blood pressure control is set at \<120/70 mmHg. For participants whose clinic blood pressure exceeds 140/90 mmHg, an unscheduled visit will be arranged within one month. If elevated clinic blood pressure persists during this visit, a 24-hour Ambulatory Blood Pressure Monitoring (ABPM) will be conducted. If the ABPM results indicate daytime blood pressure ≥135/85 mmHg, open-label add-on antihypertensive therapy will be initiated, prioritizing the use of antihypertensive medications outside of the study drugs to achieve blood pressure control.
Trial: NCT05861466
Drug: intra-vitreal injection of Ranibizumab
RxNorm normalized name: ranibizumab Injection
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The intravitreal injection will be performed with ranibizumab (0.5 mg/0.05 mL through a 27-gauge needle that will be inserted into the sclera 3.5 mm from the corneal limbus in pseudophakic patients, and 4 mm in phakic patients.
Trial: NCT05019690
Drug: Apatinib Mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet,QD,Q3W
Trial: NCT05019690
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects receive Albumin-Bound Paclitaxel,ivgtt, Strength: 125 mg/m\^2,d1、7、15,Q3W
Trial: NCT06223711
Drug: durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab is administered in fixed dose 1500mg in q3w cycles concomitant to chemotherapy and q4w cycles during maintenance treatment
Trial: NCT05093855
Drug: BDB-001 Injection
RxNorm normalized name: BDB 001
DrugBank: BDB-001 (DB16480)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple IV infusions of BDB-001 Injection diluted in sodium chloride
Trial: NCT06785844
Drug: Botulinum Toxin A (Botox )
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum Toxin injection
Trial: NCT06782529
Drug: Triamcinolone Acetonide Low Dose
RxNorm normalized name: triamcinolone acetonide Metered Dose Inhaler
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive a reduced dose of 20mg of triamcinolone acetonide.~Total injection volume of 5ml, consisting of:~* 0.5ml triamcinolone acetonide (20mg)~* 4.5ml lidocaine (45mg)
Trial: NCT06782529
Drug: Triamcinolone Acetonide Standard Dose
RxNorm normalized name: triamcinolone acetonide Metered Dose Inhaler
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive the standard of care dose of 40mg triamcinolone acetonide~Total injection volume of 5ml, consisting of:~* 1ml triamcinolone acetonide (40mg)~* 4ml lidocaine (40mg)
Trial: NCT05723198
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally
Trial: NCT06783127
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib given according the clinical practice to BRCA positive mCRPC patients
Trial: NCT05708521
Drug: Personalization of dose and frequency and instituting a tapering protocol of hydromorphone post-orthognathic surgery
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: POP participants will be given a personalized opioid prescription with a tapering protocol based on their last inpatient 24-hour usage of opioids, obtained from the nursing medication administration record. Should a participant stay in the hospital for less than 24 hours (e.g. patient had an early discharge at 18 hours), the 24-hour in-patient opioid usage would be extrapolated from their total amount and frequency of opioid use. The participant will be provided with an instruction card with suggestions on how much opioid to take at various time points following discharge to safely taper their medication.
Trial: NCT05708521
Drug: Standardized dose and frequency of hydromorphone with no tapering post-orthognathic surgery
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SOP participants will be given a standardized dose of hydromorphone (2-4mg orally every 6 hours), and a total amount of 40mg. No further information is provided to them with regards to their pain medication and to tapering.
Trial: NCT05414422
Drug: PCN-101
RxNorm normalized name: penicillin B
DrugBank: Pheneticillin (DB13337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrate for solution for infusion
Trial: NCT05849038
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive baricitinib at a dose of 2 mg oral daily.
Trial: NCT06435936
Drug: Single Ascending Dose of SAB-176
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose
Trial: NCT04846634
Drug: Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A cycle of treatment is defined as 21 days of once daily treatment.
Trial: NCT04846634
Drug: Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A cycle of treatment is defined as 21 days of once daily treatment.
Trial: NCT04846634
Drug: Penpulimab+Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A cycle of treatment is defined as 21 days of once daily treatment.
Trial: NCT05414500
Drug: Mogamulizumab
RxNorm normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV
Trial: NCT05414500
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV
Trial: NCT05676203
Drug: Standard Darolutamide
RxNorm normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2x600 mg/d as prescribed by the treating physician
Trial: NCT05676203
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel
Trial: NCT06783166
Drug: Dapagliflozin 10mg
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10 mg is a medication classified as a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
Trial: NCT06783166
Drug: Acetazolamide 500mg
RxNorm normalized name: ACETAZOLAMIDE 500MG CAP,SA
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide 500 mg is a medication classified as a carbonic anhydrase inhibitor.
Trial: NCT06095986
Drug: Aramchol meglumine
RxNorm normalized name: Meglumine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aramchol meglumine is derived from a weak acid (Aramchol) and an amino-sugar (meglumine)
Trial: NCT06701903
Drug: ITI-1284 10 mg
RxNorm normalized name: Arthur Itis
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ITI-1284 10 mg tablet, taken once daily, sublingual administration.
Trial: NCT06701903
Drug: ITI-1284 20 mg
RxNorm normalized name: Arthur Itis
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ITI-1284 20 mg tablet, taken once daily, sublingual administration.
Trial: NCT06294912
Drug: Artemether/lumefantrine
RxNorm normalized name: Artemether/lumefantrine
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets to be administered orally as definitive antimalarial treatment.
Trial: NCT06294912
Drug: Primaquine
RxNorm normalized name: Primaquine
DrugBank: Primaquine (DB01087)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets to be administered orally as definitive antimalarial treatment.
Trial: NCT06294912
Drug: Artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous (IV) infusion to be administered as definitive antimalarial treatment.
Trial: NCT06294912
Drug: Atovaquone/proguanil
RxNorm normalized name: ATOVAQUONE/PROGUANIL
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets to be administered orally as definitive antimalarial treatment.
Trial: NCT05686408
Drug: TNX-601 ER
RxNorm normalized name: TNX-901
DrugBank: TNX-901 (DB05797)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 1 tablet orally once daily for 6 weeks.
Trial: NCT06785935
Drug: Corticosteroid: Betamethasone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ultrasonography-guided corticosteroid injection under the A1 pulley
Trial: NCT06046040
Drug: TmPSMA-02 CAR T Cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TmPSMA-02 CAR T cells: autologous T cells transduced with a lentiviral vector to express an anti-PSMA CAR containing a humanized J591-derived scFv and CD2 co-stimulatory domain, and dually armored with a TGFβRDN and PD1.CD28 switch receptor.
Trial: NCT05343754
Drug: Hyperbaric oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperbaric treatment will consist of 30 daily treatments in the first 6 weeks of the study, except during the weekends. After compression for 10 minutes patients will receive 80minutes (4 times 20 minutes) 100% O2 with 3 airbrakes (21% O2) of 5 minutes at 2.4-2.5 ATA, and then 10 minutes decompression with the first part of decompression till 0.3 ATA with 100% oxygen (this will usually take seven minutes). The last 0.3 ATA will be decompressed with air. In total one hyperbaric session will be 110 minutes. Treatment will start directly at the beginning of the study.
Trial: NCT04554888
Drug: Doxepin Topical
RxNorm normalized name: doxepin topical
DrugBank: Doxepin (DB01142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Four of the areas will be treated with doxepin for 1 hour and 30 minutes (with a patch to deposit 1.2 grams of cream). Each patch will be covered with Tegaderm I.V., an occlusive, adhesive dressing (3M), for at least 1½ hours
Trial: NCT04554888
Drug: Papain
RxNorm normalized name: Papain
DrugBank: Papain (DB11193)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papain will be applied by 1 SPT prick thought the skin
Trial: NCT04554888
Drug: Histamine
RxNorm normalized name: Histamine
DrugBank: Histamine (DB05381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Histamine will be applied by 1 SPT prick thought the skin
Trial: NCT04817670
Drug: VIT-2763 120 mg
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive 2 capsules of VIT-2763 30 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally.
Trial: NCT04817670
Drug: VIT-2763 360 mg
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive 2 capsules of VIT-2763 60 mg in the morning, in the afternoon and in the evening for 8 weeks.~Capsules are to be taken orally.
Trial: NCT04817670
Drug: VIT-2763 240 mg
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive 2 capsules of VIT-2763 60 mg in the morning and in the evening, for 8 weeks.~Capsules are to be taken orally.
Trial: NCT05655598
Drug: Palbociclib Oral Product
RxNorm normalized name: palbociclib Oral Product
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 125 mg/day (FDA approved dose) or the last tolerated dose before progression for 21 days of a 28-day cycle
Trial: NCT05655598
Drug: TAS-116
RxNorm normalized name: TAS-116
DrugBank: TAS-116 (DB14876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
Trial: NCT05655598
Drug: TAS-116
RxNorm normalized name: TAS-116
DrugBank: TAS-116 (DB14876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
Trial: NCT05655598
Drug: TAS-116
RxNorm normalized name: TAS-116
DrugBank: TAS-116 (DB14876)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/day, 5 days on 2 days off, for days 1-28 of a 28 day cycle
Trial: NCT04686539
Drug: CBD
RxNorm normalized name: CBD
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: CBD oil not containing THC, to be administered sub-lingual.
Trial: NCT05547828
Drug: Tislelizumab combined with chemoradiotherapy
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab: According to the instructions of tislelizumab, 200 mg intravenously on the first day of each cycle, 21 days as a cycle.~Nab-paclitaxel: white purple: 100mg/m2 intravenous infusion on d1.8.15 (during chemotherapy) 100mg/m2 intravenous infusion q3w ╳ 3 cycles (during consolidation therapy) Radiotherapy: 40Gy/20f, 5 times/w, (esophageal primary tumor and metastatic lymph nodes)
Trial: NCT05022303
Drug: Larazotide Acetate
RxNorm normalized name: Larazotide
DrugBank: Larazotide (DB05645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.
Trial: NCT05379179
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study will compare patient-reported pain scores after receiving either ketamine or fentanyl for the treatment of acute pain due to a rattlesnake bite.
Trial: NCT04657003
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05902988
Drug: VLS-1488
RxNorm normalized name: VL-2397
DrugBank: VL-2397 (DB17796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VLS-1488 tablets will be given orally.
Trial: NCT05434156
Drug: ELE-101
RxNorm normalized name: HYDROXYPROPYL CELLULOSE (TYPE EL)
DrugBank: Hydroxypropyl cellulose (DB00840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELE-101 solution for intravenous infusion
Trial: NCT06679556
Drug: Strength A Sublingual Minoxidil
RxNorm normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One single dose of Strength A sublingual minoxidil
Trial: NCT06679556
Drug: Strength B Sublingual Minoxidil
RxNorm normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One single dose of Strength B sublingual minoxidil
Trial: NCT04325802
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg Naltrexone daily
Trial: NCT06090266
Drug: OR502
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IgG1 monoclonal antibody that binds specifically to the LILRB2 protein.
Trial: NCT06090266
Drug: Cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IgG4 mAb that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2.
Trial: NCT05493111
Drug: AR-15512 vehicle ophthalmic solution
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients administered via topical ocular instillation
Trial: NCT06192693
Drug: Capsulized fecal microbiota transfer containing the healthy feces + stool dilution solution
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 FMT=30 capsulized FMT given during 2 days in several intakes per day (3 intakes per day).~FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%.
Trial: NCT05527418
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dasatinib monotherapy 70 mg/day, during 16 weeks.
Trial: NCT06295822
Drug: Nuan-gong-ye
RxNorm normalized name: Cha Ye
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this study, the ingredients of nuan-gong-ye are myrrh, dragon's blood, yanhu tuber, white mustard seed, asarum root, argy wormwood leaf, holly oil, clove oil, cinnamon bark oil, glycerin, PEG400.
Trial: NCT05233397
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For \< 30 kg: 12 mg/kg IV every 2 weeks; For ≥30 kg: 8 mg/kg IV every 2 weeks
Trial: NCT05045482
Drug: Saroglitazar Magnesium 1 mg
RxNorm normalized name: pitavastatin magnesium 1 MG
DrugBank: Saroglitazar (DB13115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-8: Total of 18 subjects will be enrolled in the Group-8. Group 8A (n=6, consist of mild hepatic impairment subjects); Group 8B (n=6, consist of moderate hepatic impairment), Group 8C (n=3, consist of severe hepatic impairment and Group 8D (n=3, consist of control subjects with normal hepatic functions).
Trial: NCT05045482
Drug: Saroglitazar Magnesium 2 mg
RxNorm normalized name: pitavastatin magnesium 2 MG
DrugBank: Saroglitazar (DB13115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-9: Total of 12 subjects will be enrolled in the Group-9. Group 9A (n=3, consist of mild hepatic impairment subjects); Group 9B (n=3, consist of moderate hepatic impairment), Group 9C (n=3, consist of severe hepatic impairment and Group 9D (n=3, consist of control subjects with normal hepatic functions).
Trial: NCT06351540
Drug: Cannabis
RxNorm normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cannabis with 0, 5, or 30 mg THC will be inhaled via vaporization
Trial: NCT04774718
Drug: Alectinib
RxNorm normalized name: Alectinib
DrugBank: Alectinib (DB11363)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive twice-daily alectinib capsules on Days 1-28 of each 28-day cycle
Trial: NCT04703686
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1000mg - prephase - one infusion at D-3
Trial: NCT04703686
Drug: RO7082859
RxNorm normalized name: Anti-CD20/CD3 bispecific monoclonal antibody RO7082859
DrugBank: Glofitamab (DB16371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg D1C1, 10 mg D3C1, then 30 mg D8C1 and D1 every 21 days (C2-C11, D1C2 starts 14 days after D1C1)
Trial: NCT05470595
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab (IMP) will be added to Platinum/Etoposide (Standard-of-Care). Four cycles of combined immunochemotherapy 3qw will be follows by maintenance with atezolizumab monotherapy until progression.
Trial: NCT05367245
Drug: Cal-Mag Butyrate
RxNorm normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplements